<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200918048748N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-02</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of gabapentin and oral pregabalin on spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effect of preoperative use of oral gabapentin and pregabalin on spinal anesthesia characteristics and side effects</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51184</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in this study is done as permuted block randomization with hexagonal blocks of letters A, B and C and two of each (15 blocks),  each of them will be labeled by codes 1 to 15 and then using the table of random numbers numbers 1 to 15 will be selected and finally a sequence of letters A, B and C will be created. The letters represent each of the study groups and after entering the study, patients receive one of the medications prescribed by the nurse. The drugs are prepared in the same containers and in the form of capsules with the same and uniform pustules. The person prescribing the medication is different from the person filling out the checklist.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group A with 300 mg of oral gabapentin made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L5-L4 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric bupivacaine for patients. Intervention 2: Intervention group: Group B, 150 mg Pregabalin made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L4-L5 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric Bupivacaine for patients. Intervention 3: Control group: Group C Oral placebo، Placebo capsule made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L4-L5 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric Bupivacaine for patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main outcome, can be shared.

When:
Access period starts from 2020-2021

To whom:
Researchers

Conditions:
For application or additional studies

Where to obtain:
Send mail to n.barzegar87@gmail.com

How to obtain:
Request in person or by e-mail

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Niloofar Barzegar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan University of medical sciences-Qotbe Ravandi Blvd</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8739118631</zip>
        <telephone>+98 31 5550 0111</telephone>
        <email>n.barzegar87@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mohammad Reza Razavizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sabaye dahom alley; Zanbagh alley; Golha alley; Kashan-Amir Kabir street</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8739118631</zip>
        <telephone>+98 31 5554 0026</telephone>
        <email>mr_razavzi48@yahoo.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being at the age of 18-70 years 
ASA class 1-2
undergoing orthopedic elective surgery with spinal anesthesia below the T10 level
Duration of surgery less than 2 hours</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Weight less than 40 kg
Hypersensitivity to pregabalin
Hypersensitivity to the drug gabapentin
Allergy to bupivacaine
Localized sepsis at the injection site of the spinal needle
Pregnancy and lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O89.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Spinal and epidural anesthesia-induced headache during the puerperium</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group A with 300 mg of oral gabapentin made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L5-L4 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric bupivacaine for patients.</i_keyword>
      <i_keyword>Intervention group: Group B, 150 mg Pregabalin made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L4-L5 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric Bupivacaine for patients.</i_keyword>
      <i_keyword>Control group: Group C Oral placebo، Placebo capsule made in Iran and Abidi Pharmaceutical Company, Patients receive this substance 2 hours before surgery. In sterile conditions after skin anesthesia with 2 CC lidocaine 2%, spinal anesthesia using cutting needle 25 and through the space between L4-L5 and L3-L4 vertebrae in The midline is performed with 15 mg of 0.5% hyperbaric Bupivacaine for patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sensory block start time. Timepoint: It is measured and recorded every 5 minutes until the end of the operation and every 15 minutes in recovery for up to two hours. Method of measurement: Based on the Visual Analogue Scale and recorded in the checklist.</prim_outcome>
      <prim_outcome>Duration of anesthesia. Timepoint: It is measured and recorded every 5 minutes until the end of the operation and every 15 minutes in recovery for up to two hours. Method of measurement: Based on the Visual Analogue Scale and recorded in the checklist.</prim_outcome>
      <prim_outcome>Postoperative nausea and vomiting. Timepoint: They are measured and recorded every 5 minutes until the end of the operation and every 15 minutes in recovery for up to two hours. Method of measurement: The incidence and severity of postoperative nausea and vomiting are assessed based on the simplified criterion of postoperative nausea and vomiting (PONV scale).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-01</approval_date>
        <contact_name>Ethics Committee of Kashan University of Medical Sciences</contact_name>
        <contact_address>Kashan University of Medical Sciences; Parstar boulevard; Qutb Ravandi boulevard Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
